Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults
In older adults, 24-valent pneumococcal conjugate vaccine was clinically and economically unfavorable compared with 21-valent pneumococcal conjugate vaccine, which covers more adult disease-causing pneumococcal serotypes and is less susceptible to childhood vaccination indirect effects.
Authors
- Kenneth J. Smith (ORCID: https://orcid.org/0000-0001-8088-566X)
- Richard Kent Zimmerman (ORCID: https://orcid.org/0000-0001-5941-6092)
- William Schaffner (ORCID: https://orcid.org/0000-0002-1375-8078)
- Angela R. Wateska (ORCID: https://orcid.org/0000-0003-4541-0161)
- Chyongchiou J. Lin (ORCID: https://orcid.org/0000-0001-9441-3508)
- Mary Patricia Nowalk (ORCID: https://orcid.org/0000-0002-1702-2690)
- Lee H. Harrison (ORCID: https://orcid.org/0000-0002-3787-2705)
Institutions
- University of Pittsburgh (US)
- Vanderbilt University (US)
- UPMC Health System (US)
- University of Pittsburgh Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- American Journal of Preventive Medicine
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1016/j.amepre.2024.11.014
- Citations
- 8
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 3.09
Funders
- Pfizer
- Sanofi
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Sanofi Pasteur
- National Institute of Allergy and Infectious Diseases